Prof Iain B McInnes CBE PhD FRCP FRSE FAMedSci Prof. McInnes is the Director of the Institute of Infection, Immunity and Inflammation in the University of Glasgow. He is a clinician-scientist and brings a long and successful track record in the conduct of clinical trials in rheumatology. He was elected a fellow of the Royal Society of Edinburgh in 2008, and a Fellow of the Academy of Medical Sciences in 2012. Iain is currently President of the European League Against Rheumatism. Additionally, Iain sits on the advisory boards of Pfizer; BMS; AstraZeneca; Janssen; Novartis and NovoNordisk.
Professor George AC Murrell is an orthopaedic surgeon and Director of the Orthopaedic Research Institute at St George Hospital and Professor at the UNSW. Professor Murrell specialises in shoulder surgery. He serves on the editorial boards of the Journal of Shoulder and Elbow Surgery and Elbow Surgery, Techniques in Shoulder and Elbow Surgery and the British Journal of Sports Medicine. Prof. Murrell is an internationally recognised Key Opinion Leader in Tendinopathies.
Dr Neil Gibson brings more than 25 years of drug development experience to Causeway. Neil has held various senior positions within the biotechnology and pharmaceutical industry including senior vice president, BioAtla; chief scientific officer, Regulus Therapeutics; chief scientific officer and oncology therapeutic area head, Pfizer Oncology; and chief scientific officer, OSI Pharmaceuticals. While at Pfizer, Dr. Gibson was also a member of the Pfizer Oncology Business Unit Executive team. Dr. Gibson has been involved in the successful discovery, development, and commercialization of four approved oncology drugs, including temozolomide, sorafenib, erlotinib, and crizotinib. While at Regulus, Dr. Gibson was responsible for leading all research and development efforts resulting in 3 distinct oligonucleotides being advanced into clinical development and the establishment of human proof of concept with the lead molecule RG-101. Dr. Gibson has also been involved in the growth of new biotechnology organizations and significant fund raising.